Mersana Shares Rise on Advances With Breast-Cancer Treatment
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...
Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study
The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study ...
Bio-Path Holdings Provides 2025 Clinical and Operational Update
Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- , ...
Diamyd Medical AB: Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd following FDA Type C Meeting
Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration ...
US 'notorious markets' report warns of risks from online pharmacies
U.S. government report on “notorious markets” known for counterfeiting and other violations of intellectual property says ...
Pharmaceutical Technology27m
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.
Bryan Johnson, who gulps down 54 pills for breakfast, ditches longevity drug rapamycin. Here's why
Bryan Johnson, a 47-year-old US software millionaire, had made waves with his ambitious mission to reverse ageing. Now, the ...
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.